XML 46 R37.htm IDEA: XBRL DOCUMENT v3.25.3
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 30, 2013
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue   $ 1,076 $ 123 $ 5,163 $ 26,486
AstraZeneca Agreements [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue   $ 165,300 $ 42,200 218,600 $ 115,300
AstraZeneca Agreements [Member] | U.S./RoW [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Aggregate considerations received       439,000  
AstraZeneca Agreements [Member] | China [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront, non-contingent, non-refundable and time-based payments $ 376,700        
Aggregate considerations received       $ 81,200